Key Developments: Horizon Pharma PLC (HZNP.O)

HZNP.O on Nasdaq

12.94USD
31 Oct 2014
Price Change (% chg)

$0.19 (+1.49%)
Prev Close
$12.75
Open
$12.90
Day's High
$13.15
Day's Low
$12.60
Volume
1,668,361
Avg. Vol
1,689,591
52-wk High
$18.30
52-wk Low
$3.70

Search Stocks

Latest Key Developments (Source: Significant Developments)

Horizon Pharma PLC announces acquisition of U.S. rights to PENNSAID 2 pct from Nuvo Research Inc.
Friday, 17 Oct 2014 07:00am EDT 

Horizon Pharma PLC:Says acquisition of the U.S. rights to PENNSAID 2 pct w/w (PENNSAID 2 pct) from Nuvo Research Inc. for a one-time payment of $45 mln in cash.PENNSAID 2 pct is approved in the U.S. for the treatment of the pain of osteoarthritis (OA) of the knee(s).  Full Article

Horizon Pharma PLC receives orphan-drug designation for actimmune in Friedreich's Ataxia
Friday, 3 Oct 2014 04:00pm EDT 

Horizon Pharma PLC:Announces that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for ACTIMMUNE (Interferon gamma-1b) for the treatment of Friedreich's ataxia (FA), a rare, genetic disease for which there are currently no approved treatments.The U.S. Orphan Drug Act (ODA) provides for granting special status to a drug or biological product to treat a rare disease or condition that affects fewer than 200,000 patients in the United States.Orphan designation qualifies the sponsor of the drug for various development incentives, including tax credits for qualified clinical testing.  Full Article

Horizon Pharma Inc reaffirms FY 2014, 2015 guidance
Friday, 19 Sep 2014 10:43am EDT 

Horizon Pharma Inc:Reaffirms FY 2014 net sales guidance of $270 to $280 mln.Reaffirms FY 2014 adjusted EBITDA of $80 to $90 mln.Reaffirms FY 2015 net sales guidance of $380 to $405 mln.Reaffirms FY 2015 adjusted EBITDA of $150 to $170 mln.FY 2014 revenue of $277 mln - Thomson Reuters I/B/E/8.FY 2015 EBITDA of $160 mln - Thomson Reuters I/B/E/S.  Full Article

Horizon Pharma completes acquisition of Vidara Therapeutics International plc
Friday, 19 Sep 2014 10:43am EDT 

Horizon Pharma:Completed the acquisition of Vidara Therapeutics International plc.Says in connection with the acquisition, Horizon and Vidara have combined with the resulting parent company incorporated in Ireland and named Horizon Pharma Public Limited Company, or plc.Under the terms of the transaction, stockholders of Horizon Pharma, Inc. received one ordinary share of Horizon Pharma plc in exchange for each share of Horizon Pharma, Inc. common stock they owned at closing.  Full Article

Horizon Pharma Inc reiterates FY 2014 guidance; gives FY 2015 guidance; revenue guidance above analysts' estimates
Thursday, 7 Aug 2014 06:30am EDT 

Horizon Pharma Inc:Reiterates prior net sales guidance range for FY 2014 of $270 mln to $280 mln and adjusted EBITDA range of $80 mln to $90 mln.Provides preliminary net sales guidance for FY 2015 in range of $380 mln to $405 mln and preliminary adjusted EBITDA guidance of $150 mln to $170 mln.FY 2015 revenue of $352 mln and EBITDA of $163 mln - Thomson Reuters I/B/E/S.  Full Article

Horizon Pharma Inc announces execution of $300 mln senior secured credit agreement in connection with the proposed acquisition of Vidara
Thursday, 19 Jun 2014 07:00am EDT 

Horizon Pharma Inc:Entered into an agreement with group of lenders to provide Horizon with $300 mln in financing through five year senior secured credit facility.Funding is expected to occur coincident with closing of proposed acquisition of Vidara Therapeutics International Ltd.Agreement replaces $250 MLN bridge loan commitment received from Deerfield Management Company, L.P., which Company announced on March 19.Intends to use proceeds to effect proposed acquisition of Vidara, pay related transaction fees and expenses and for general corporate purposes.Citigroup Global Markets Inc. and Cowen and Company, LLC and their respective affiliates are acting as joint lead arrangers and initial lenders to Horizon for the financing.  Full Article

Horizon Pharma Inc announces Robert J. De Vaere to retire and names Paul W. Hoelscher Chief Financial Officer
Wednesday, 18 Jun 2014 07:00am EDT 

Horizon Pharma Inc:Robert J. De Vaere, its Chief Financial Officer, will retire on Sept. 30.Names Paul W. Hoelscher as Executive Vice President, Finance, effective June 23 and its Chief Financial Officer, effective Oct. 1.  Full Article

Horizon Pharma Inc updates FY 2014 revenue outlook above analysts' estimates; updates FY 2014 EBITDA outlook below analysts' estimates
Friday, 9 May 2014 06:30am EDT 

Horizon Pharma Inc:Expects FY 2014 net revenues in the range of $270 to $280 mln.Expects FY 2014 adjusted EBITDA (excluding Vidara acquisition related expenses, step up in inventory required under purchase accounting related to ACTIMMUNE and other potential special items or substantive events) to be in the range of $80 to $90 mln.FY 2014 revenue of $260 mln, EBITDA of $92 mln - Thomson Reuters I/B/E/S.  Full Article

Deerfield Provides up to $250 mln in acquisition financing to Horizon Pharma
Wednesday, 19 Mar 2014 07:15am EDT 

Deerfield Management Company:Provides up to $250 mln in acquisition financing to Horizon Pharma, Inc. for acquisition of Vidara Therapeutics International Ltd.Horizon Pharma has option to draw up to $250 mln in exchange for commitment fee.Amounts drawn will accrue interest payable quarterly in arrears and must be repaid within five years.  Full Article

Horizon Pharma Inc to Acquire Vidara Therapeutics International Ltd
Wednesday, 19 Mar 2014 07:00am EDT 

Horizon Pharma Inc:Says the company and Vidara Therapeutics International Ltd have entered into a definitive agreement under which Horizon Pharma will acquire Vidara through a reverse merger for stock and cash valued at about $660 million.Horizon Pharma plc will be the name of the resulting company.The proposed transaction has been unanimously approved by both companies' boards.Vidara will combine with Horizon with about 74 percent of Horizon's ordinary shares to be exchanged for Horizon's common shares, with Horizon surviving the merger.The shareholders of Vidara will retain about 26 percent of Horizon Pharma plc and receive $200 million in cash.  Full Article

Search Stocks